{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:11:24Z","timestamp":1788307884049,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":469,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) in the post-approval era of tafamidis 61 mg are lacking. Study aims were characterization of contemporary ATTR-CM patients, analysis of potential eligibility for the \u2018Transthyretin Amyloidosis Cardiomyopathy Clinical Trial\u2019 (ATTR-ACT) and identification of factors associated with the decision on tafamidis 61 mg treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This retrospective study analysed ATTR-CM patients seen at eight University Hospitals in the first year after approval of tafamidis 61 mg for ATTR-CM in Germany (April 2020 to March 2021). The cohort comprised 366 patients (median age 79 [74; 82] years, 84% male), with 47% and 45% of the cohort being in National Amyloidosis Centre ATTR stage \u2265 II and NYHA class \u2265 III, respectively. Sixty-four per cent of patients met key eligibility criteria of the pivotal ATTR-ACT. In recently diagnosed patients (58% with diagnosis \u22646 months), the rate of variant ATTR was significantly lower than in patients diagnosed more than 6 months ago (9.3% vs. 19.7%). Of the 293 patients without prior ATTR specific treatment, tafamidis 61 mg was newly initiated in 77%. Patients with tafamidis 61 mg treatment were significantly younger, were more often eligible for ATTR-ACT, had lower NYHA class and higher serum albumin levels. These variables explained 16% of the variance of treatment decision. Unadjusted survival was higher in patients with than those without treatment (1-year survival 98.6% vs. 87.3%, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Wild-type ATTR was the primary aetiology amongst contemporary ATTR-CM patients and almost two-thirds of patients were in an advanced disease stage. Clinical profiles of 64% of patients in routine care matched those of the ATTR-ACT. Further effort is needed to detect patients at an earlier disease stage and to validate criteria justifying treatment initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15126","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T19:46:44Z","timestamp":1730922404000},"page":"1203-1216","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational Study"],"prefix":"10.1093","volume":"12","author":[{"given":"Richard J.","family":"Nies","sequence":"first","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Ney","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Kindermann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Bewarder","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Knebel","sequence":"additional","affiliation":[{"name":"Sana Klinikum Berlin Lichtenberg , Berlin ,","place":["Germany"]},{"name":"Klinik f\u00fcr Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charit\u00e9 , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charit\u00e9 , Berlin ,","place":["Germany"]},{"name":"Klinik f\u00fcr Neurologie mit Experimenteller Neurologie, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charit\u00e9 , Berlin ,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"Amyloidosis Center Charit\u00e9 Berlin (ACCB), Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Luedike","sequence":"additional","affiliation":[{"name":"West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[{"name":"West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[{"name":"West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papathanasiou","sequence":"additional","affiliation":[{"name":"West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen , Essen ,","place":["Germany"]},{"name":"Department of Cardiology, University Hospital Frankfurt , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Epidemiology, Department of Medicine I, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cejka","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Epidemiology, Department of Medicine I, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Polzin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, University Duesseldorf, Medical Faculty, Cardiovascular Research Institute D\u00fcsseldorf (CARID) , Duesseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Voss","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, University Duesseldorf, Medical Faculty, Cardiovascular Research Institute D\u00fcsseldorf (CARID) , Duesseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kelm","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, University Duesseldorf, Medical Faculty, Cardiovascular Research Institute D\u00fcsseldorf (CARID) , Duesseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Uns\u00f6ld","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Cardiology and Angiology, Justus-Liebig-University Giessen , Giessen ,","place":["Germany"]},{"name":"Department of Internal Medicine II, University Hospital Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Meindl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie I, Sektion f\u00fcr Herzbildgebung, Universit\u00e4tsklinikum M\u00fcnster , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwas","family":"Chamling","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie I, Sektion f\u00fcr Herzbildgebung, Universit\u00e4tsklinikum M\u00fcnster , M\u00fcnster ,","place":["Germany"]},{"name":"Department of Internal Medicine B, University Medicine Greifswald and DZHK (German Centre for Cardiovascular Research) partner site Greifswald , Greifswald ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Epidemiology, Department of Medicine I, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2026021803584663000_ehf215126-bib-0001","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021803584663000_ehf215126-bib-0002","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0003","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"Bezard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0004","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0005","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021803584663000_ehf215126-bib-0006","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021803584663000_ehf215126-bib-0007","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026021803584663000_ehf215126-bib-0008","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective","volume":"133","author":"Connors","year":"2016","journal-title":"Observ Cohort Study Circ"},{"key":"2026021803584663000_ehf215126-bib-0009","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026021803584663000_ehf215126-bib-0010","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00392-022-02114-y","article-title":"Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018","volume":"112","author":"Ney","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0011","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"ESC guidelines for the management of cardiomyopathies","volume":"2023","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021803584663000_ehf215126-bib-0012","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1253\/circj.CJ-23-0223","article-title":"Prevalence of cardiac amyloidosis in patients undergoing carpal tunnel release with amyloid deposition","volume":"87","author":"Takashio","year":"2023","journal-title":"Circ J"},{"key":"2026021803584663000_ehf215126-bib-0013","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1253\/circj.CJ-23-0948","article-title":"Efficacy of computed tomography-based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation","volume":"88","author":"Yamasaki","year":"2024","journal-title":"Circ J"},{"key":"2026021803584663000_ehf215126-bib-0014","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/ehf2.12884","article-title":"Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"7","author":"Yamada","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0015","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026021803584663000_ehf215126-bib-0016","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021803584663000_ehf215126-bib-0017","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021803584663000_ehf215126-bib-0018","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021803584663000_ehf215126-bib-0019","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/echo.15206","article-title":"Diastolic function grading by American Society of Echocardiography guidelines and prediction of heart failure readmission and all-cause mortality in a community-based cohort","volume":"38","author":"Lavine","year":"2021","journal-title":"Echocardiography"},{"key":"2026021803584663000_ehf215126-bib-0020","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026021803584663000_ehf215126-bib-0021","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026021803584663000_ehf215126-bib-0022","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","article-title":"Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"8","author":"Sperry","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0023","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026021803584663000_ehf215126-bib-0024","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026021803584663000_ehf215126-bib-0025","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ehf2.14220","article-title":"Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy","volume":"10","author":"Iwaya","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0026","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2021.11.048","article-title":"Temporal trends in diagnostic testing patterns for wild-type transthyretin amyloid cardiomyopathy in the Medicare fee-for-service population","volume":"167","author":"Bourque","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0027","volume-title":"Full prescribing information on Vyndaqel and Vyndamax","author":"Pfizer Europe MA EEIG","year":"2023"},{"key":"2026021803584663000_ehf215126-bib-0028","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0029","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ahj.2010.12.024","article-title":"Performance-based functional assessment of patients undergoing transcatheter aortic valve implantation","volume":"161","author":"Bagur","year":"2011","journal-title":"Am Heart J"},{"key":"2026021803584663000_ehf215126-bib-0030","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00392-023-02163-x","article-title":"Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany","volume":"113","author":"Morbach","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0031","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis-a clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"key":"2026021803584663000_ehf215126-bib-0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0033","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"},{"key":"2026021803584663000_ehf215126-bib-0034","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0036","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40256-022-00563-4","article-title":"Real-world characteristics of patients with wild-type transthyretin amyloid cardiomyopathy: an analysis of electronic healthcare records in the United States","volume":"23","author":"Bhambri","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021803584663000_ehf215126-bib-0037","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12199-021-00946-0","article-title":"Lower albumin levels are associated with frailty measures, trace elements, and an inflammation marker in a cross-sectional study in Tanushimaru","volume":"26","author":"Yamamoto","year":"2021","journal-title":"Environ Health Prev Med"},{"key":"2026021803584663000_ehf215126-bib-0038","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021803584663000_ehf215126-bib-0039","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026021803584663000_ehf215126-bib-0040","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ejhf.2658","article-title":"Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy","volume":"24","author":"Maestro-Benedicto","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/1203\/66952945\/eschf_12_2_1203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/1203\/66952945\/eschf_12_2_1203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:58:54Z","timestamp":1771405134000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/2\/1203\/8487949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15126","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2024-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}